Latest Ratios: P/E Ratio -1.7x · EV/EBITDA N/A · ROE -145.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $93M | $186M | $102M | — | — | — | — | — | — | — | — |
| Enterprise Value | $-14086019 | $79M | $46M | — | — | — | — | — | — | — | — |
| P/E Ratio → | -1.66 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 26.72 | 53.24 | 156.16 | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.80 | 3.90 | 1.61 | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 22.50 | 71.21 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.1% | 53.1% | 100.0% | 100.0% | — | 41.2% | 39.7% | 39.1% | 40.6% | 41.2% | 40.8% |
| Operating Margin | -1488.3% | -1488.3% | -8142.3% | -14822.6% | — | -5.2% | -1.3% | -4.6% | 5.4% | 2.2% | 0.4% |
| Net Profit Margin | -2298.5% | -2298.5% | -7943.4% | -14083.1% | — | -10.5% | -6.9% | -21.5% | 5.1% | 4.5% | -2.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -145.1% | -145.1% | -82.0% | — | -3335.2% | -34.7% | -17.8% | -45.9% | 9.1% | 9.2% | -4.0% |
| ROA | -82.0% | -82.0% | -77.7% | -62.6% | -17.5% | -7.4% | -4.5% | -14.3% | 3.4% | 3.8% | -1.8% |
| ROIC | — | — | — | — | -135.2% | -5.5% | -1.2% | -5.1% | 6.6% | 2.7% | 0.5% |
| ROCE | -60.9% | -60.9% | -91.7% | -73.2% | -22.4% | -4.8% | -1.1% | -3.8% | 4.4% | 2.2% | 0.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.14 | — | — | 2.61 | 2.12 | 1.70 | 1.34 | 0.78 | 0.90 |
| Debt / EBITDA | — | — | — | — | — | 27.92 | 11.63 | 15.41 | 6.95 | 4.99 | 5.92 |
| Net Debt / Equity | — | -2.25 | -0.88 | — | — | 1.47 | 1.20 | 0.92 | 0.09 | 0.11 | 0.32 |
| Net Debt / EBITDA | — | — | — | — | — | 15.76 | 6.57 | 8.35 | 0.49 | 0.70 | 2.14 |
| Debt / FCF | — | — | — | — | — | — | 6.91 | — | 0.52 | 0.37 | 2.98 |
| Interest Coverage | — | — | — | — | -7.19 | -1.00 | -0.25 | -0.83 | 1.18 | 0.77 | 0.14 |
Net cash position: cash ($110M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.35 | 7.35 | 6.92 | 5.13 | 10.62 | 2.04 | 2.00 | 1.96 | 4.83 | 2.89 | 2.70 |
| Quick Ratio | 7.35 | 7.35 | 6.92 | 5.13 | 10.62 | 1.83 | 1.70 | 1.66 | 4.44 | 2.51 | 2.32 |
| Cash Ratio | 7.06 | 7.06 | 6.67 | 4.92 | 10.47 | 0.96 | 0.85 | 0.88 | 3.28 | 1.63 | 1.31 |
| Asset Turnover | — | 0.03 | 0.01 | 0.01 | — | 0.74 | 0.70 | 0.74 | 0.60 | 0.77 | 0.86 |
| Inventory Turnover | — | — | — | — | — | 8.62 | 5.79 | 6.06 | 6.74 | 5.92 | 7.10 |
| Days Sales Outstanding | — | 16.17 | 60.46 | 460.94 | — | 72.29 | 80.26 | 72.05 | 78.34 | 71.40 | 70.07 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $30M | $20M | $12M | $36M | $35M | $34M | $34M | $35M | $36M | $36M |
Clinical trial execution failure
According to recent market data, CAMP trades at a price-to-sales multiple of 25.50, which suggests that investors are pricing the company as a speculative platform play rather than a traditional healthcare entity, as the valuation is disconnected from current revenue generation and relies entirely on future clinical milestones.
The elevated P/S ratio reflects the market's anticipation of the regRNA platform's potential rather than any near-term earnings power. Investors should monitor whether this premium holds as the company progresses through clinical trials, as any delay in the CMP-135 program could lead to significant valuation compression.
Based on reported figures, CAMP's return on invested capital has remained deeply negative, with recent quarterly readings like -109.9% in 2025Q1 highlighting the company's inability to generate positive returns on its capital base while it continues to fund intensive, early-stage research and development activities.
The persistent negative ROIC is a structural feature of a pre-revenue biotech firm that must prioritize scientific validation over immediate capital efficiency. This trend suggests that shareholders should expect continued value dilution until the company can demonstrate a clear path toward commercializing its proprietary gene regulation technology.
As reported in financial statements, the company's asset turnover ratio remains negligible at 0.01, which confirms that the firm is not currently generating meaningful revenue from its asset base and is instead focused on the long-term development of its internal research and development pipeline.
The erratic nature of the cash conversion cycle and working capital metrics suggests that the company's operational efficiency is secondary to its clinical development timeline. Investors should interpret these low turnover figures as a sign that the firm is in a capital-intensive phase where asset utilization is not yet a relevant performance indicator.
According to the latest quarterly data, CAMP maintains a current ratio of 6.15, which indicates a robust liquidity position that provides the company with a necessary buffer to sustain its high-burn research operations without the immediate requirement for additional dilutive financing in the near term.
This liquidity profile appears healthy relative to the company's historical volatility, providing management with the flexibility to navigate the clinical trial process for its lead assets. However, the reliance on cash reserves warrants further investigation, as the current burn rate remains high and could deplete these resources if clinical timelines extend.
As indicated by the company's financial disclosures, the use of P/E ratios is fundamentally misapplied to CAMP, as the firm's negative earnings and lack of commercial revenue render traditional valuation multiples meaningless for assessing the true economic value of its proprietary regRNA platform and clinical pipeline.
Analysts should instead focus on probability-adjusted net present value models or cash runway metrics to evaluate the company's potential. Relying on P/E or EBITDA multiples obscures the reality that the firm is currently an R&D engine, and such metrics fail to capture the optionality inherent in its early-stage therapeutic assets.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CAMP stock.
CAMP4 Therapeutics Corporation's current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
CAMP4 Therapeutics Corporation's return on equity (ROE) is -145.1%. The historical average is -14.8%.
Based on historical data, CAMP4 Therapeutics Corporation is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CAMP4 Therapeutics Corporation has 53.1% gross margin and -1488.3% operating margin.